Technology
Explore the proprietary technologies that power our innovative therapeutic solutions.
The Innostem Advantage
Discover the proprietary technologies that give Innostem Bio a competitive edge in the field of regenerative medicine.
Our proprietary stepwise stem cell isolation and culture technology allows for 100 times efficiency of conventional methods.
- Tissue-Resident Stem Cell Platform
- Integrated homeostasis-mimicking process
- Higher & consistent yield
Our xeno-free, serum-free cryopreservation technology ensures our allogeneic cell therapeutics are ready for injection post-thaw and stable for over 3 years.
- >80% cell viability post-thaw
- No post-thaw purification needed
- Ready for immediate injection
- Compliant with USP/KP standards
Our high-potency MCB & WCB cell banks, derived from a single donor, can manufacture over 1,000 doses of therapeutic material with consistent quality and stable QC.
- Pharmaceutical-grade cGMP facility
- Consistent potency and quality
- Diverse library of stem cells
Next-Gen Stem Cell Therapy, Redefined
Our next-generation platform overcomes the limitations of traditional stem cell therapies.
| Feature | Traditional Therapy | Innostem Bio Therapy |
|---|---|---|
| Type | Autologous / Allogeneic | Allogeneic |
| Origin | Bone marrow, Fat, Cord Blood | Peripheral Nerve / Myocardium |
| Manufacture Quantity (/Donor) | One-time or <100 doses | >1,000-10,000 doses |
| Quality Control | Relative difficulty | Stable QC/QA via cell bank |
| Potency | High Variation | Uniform |
| Mechanism of Action | General | Disease-specific mode of action |
| Shelf Life | 24-48 hours (Refrigeration) | >3 years (Cryopreserved Formula)) |
| Dosage | Single Dosing | Ensuring repeated dosing with same lots |
Traditional Therapy
Autologous / Allogeneic
Innostem Bio Therapy
Allogeneic
Traditional Therapy
Bone marrow, Fat, Cord Blood
Innostem Bio Therapy
Peripheral Nerve / Myocardium
Traditional Therapy
One-time or <100 doses
Innostem Bio Therapy
>1,000-10,000 doses
Traditional Therapy
Relative difficulty
Innostem Bio Therapy
Stable QC/QA via cell bank
Traditional Therapy
High Variation
Innostem Bio Therapy
Uniform
Traditional Therapy
General
Innostem Bio Therapy
Disease-specific mode of action
Traditional Therapy
24-48 hours (Refrigeration)
Innostem Bio Therapy
>3 years (Cryopreserved Formula))
Traditional Therapy
Single Dosing
Innostem Bio Therapy
Ensuring repeated dosing with same lots
Technology Development Milestones
A timeline of our key milestones and technological breakthroughs.
1993
Start Hepatocyte Culture
%EB%B0%B0%EC%96%91.png&w=828&q=75)
1999
Expand into Organotypic Liver Culture
.png&w=828&q=75)
2003
Design Provisional Matrix-Mimicking Hydrogel
2004
Discover Adipose Stem Cells-Integrated Biofiller & Optimize a Chemical-Define Cryopreservation recipe
2006
Succeed to Discover & Isolate
- Myocardiac Stem Cells
- Skeletal Muscle Stem Cells
- Adipose Stem Cells
- Neural Crest Stem Cells
- Vascular Adventitial Stem Cells
.png&w=828&q=75)
.JPG&w=828&q=75)
2012
Adapt a Platform Technology to Isolate Synovial Stem Cells
2014
Design a One-Step Integrated Method to Manufacture a Multilayered Cell Sheet of Myocardial Stem Cells
2015
Extend a Cell Sheet Technology to Develop Neural Crest Stem Cells Cell Sheet
2016
Develop Injectable Microtissue for Wound Healing/Angiogenesis
2017
Expand into Fabricating Neural Microtissue for Neural Tissue Regeneration
2022
Develop Chemical-define Cryopreservation Formula for Cellular Biodrugs
2023
Discover a Platform Technology to Activate and Isolate uPAR+/Nestin+ High Potent Stem Cells
- Myocardium
- Peripheral Nerve
- Skeletal Muscle
- Adipose Tissue
- Synovium
- Bone Marrow MSCs
- Spinal Cord
2024
Design a Extracellular Microenvironment for Physical Cell Stretching to Produce Functional EV Production
Patent Portfolio
Our intellectual property is a testament to our commitment to innovation and leadership in regenerative medicine.
| Title | Application Number | Application Date | Registration Number | Registration Date |
|---|---|---|---|---|
| Therapeutic Composition for Adipose Tissue Disorders, and Methods for Its Preparation and Delivery | KR 10-0811537 | 2008-03-03 | ||
| Method for Culturing Cardiac Progenitor Cells and Therapeutic Applications Thereof | KR 10-1389850 | 2014-04-22 | ||
| Method for Culturing Neural Crest Stem Cells and Therapeutic Applications Thereof | KR 10-1389851 | 2014-04-22 | ||
| EP 2 845 898 | 2017-07-05 | |||
| Method for the Culture of Skeletal Muscle Stem Cells and Uses Thereof | KR 10-1389852 | 2014-04-22 | ||
| Method for Culturing Mesenchymal Stem Cells Derived from the Gastrointestinal Tract, Peripheral Nerves, or Blood Vessels, and Uses Thereof | KR 10-1389849 | 2014-04-22 | ||
| Mesenchymal Stem Cells Derived from the Synovial Membrane and Uses Thereof | KR 10-2223043 | 2021-02-25 | ||
| Method for Manufacturing Peripheral Nerve-Mimicking Microtissue and Uses Thereof | KR 10-2322635 | 2021-11-01 | ||
| PCT/KR2022/007991 | 2022-06-07 | |||
| US 18/568,851 | 2023-12-11 | |||
| JP 2023-575974 | 2023-12-08 | |||
| CN 202280050845.4 | 2024-01-18 | |||
| Cryopreservation Solution Composition for Long-Term Storage of Cellular Biopharmaceuticals | KR 10-2319110 | 2021-10-25 | ||
| PCT/KR2022/000979 | 2022-01-19 | |||
| Method for Isolating and Culturing Tissue-Resident uPAR+/Nestin+ Stem Cells and Uses Thereof | KR 10-2476348 | 2022-12-06 | ||
| PCT/KR2022/007910 | 2022-06-03 | |||
| US 18/290,155 | 2023-11-10 | |||
| EU 22 816 495.0 | 2023-11-10 | |||
| JP 7678614 | 2025-05-08 | |||
| CN 202280039679.8 | 2023-12-01 | |||
| Tissue-Resident uPAR-Positive Stem Cells and Uses Thereof | KR 10-2022-0167670 | 2022-12-05 | ||
| Method for Manufacturing Stem Cell-Derived Exosomes Through Cell Stretching and Their Applications | KR 10-2023-0169400 | 2023-11-19 | ||
| PCT/KR2024/001283 | 2024-01-26 | |||
| US, Pending | ||||
| JP, Pending | ||||
| CN, Pending |
Published Articles
Explore our peer-reviewed research that validates the efficacy and safety of our groundbreaking technologies.
Ex vivo organ culture of adipose tissue for in situ mobilization of adipose-derived stem cells and defining the stem cell niche
J of Cellular Physiol 2010;224:807
Fibrin matrix-supported three- dimensional organ culture of adipose tissue for selective outgrowth, expansion, and isolation of adipose- derived stem cells
Acta Biomaterialia 2011;7:4109
Adipose-tissue-derived stem cells enhance the healing of ischemic colonic anastomoses
J. Korean Coloproctology 2012;28(3):132
Adipose-derived stem cells on the healing of ischemic colitis: a therapeutic effect by angiogenesis
Int J of Colorectal Dis 2012;27:1437
Effect of stem cells and fibrin concentration on the vascularization of the Medpor orbital implant
Clinical and Experiment Ophthal 2010;38:885
The isolation and in situ identification of MSCs residing in loose connective tissues using a niche-preserving organ culture system
Biomaterials 2012;33:4469
Intra-articular delivery of synovium-resident mesenchymal stem cells via BMP-7-loaded fibrous PLGA scaffolds for cartilage repair
J Control Rel 2019;302:169
A fibrin-supported myocardial organ culture for isolation of cardiac stem cells via the recapitulation of cardiac homeostasis
Biomaterials 2012;48:66
Engineered extracellular microenvironment with a tunable mechanical property for controlling cell behavior and cardiomyogenic fate of cardiac stem
Acta Biomaterialia 2017;50:234
Intracellular transduction of TAT-Hsp27 fusion protein enhancing cell survivaland regeneration capacity of cardiac stem cells in acute myocardial infarction
J Control Rel 2015;215:55
Epicardial delivery of VEGF and cardiac stem cells guided by 3-dimensional PLLA mat enhancing cardiac regeneration and angiogenesis in acute myocardial infarction
J Control Rel 2015;205:218
Characterization of human cardiac mesenchymal stromal cells and their extracellular vesicles compaing with human bone marrow derived mesenchymal stem cells
BMB Rep 2020;53:118
Intracellular-type cryopreservation solution improves the cryopreservation outcome of primary human hepatocytes
Tissue Engineer Regenerative Med 2009;6:909
Peripheral Nerve-Derived Stem Cell Spheroids Induce Functional Recovery and Repair after Spinal Cord Injury in Rodents
Int J of Mol Sci 2021:22;4141
Intramyocardial delivery of human cardiac stem cell spheroids with enhanced cell engraftment ability and cardiomyogenic potential for myocardial infarct repair
J Control Rel 2021:10;499
Co-Administration of Resolvin D1 and Peripheral Nerve-Derived Stem Cell Spheroids as a Therapeutic Strategy in a Rat Model of Spinal Cord Injury
Int J Mol Sci 2023;24:10971
Repeated intrathecal injections of peripheral nerve-derived stem cell spheroids improve outcomes in a rat model of traumatic brain injury
Stem Cell Res Ther 2024:15;314